CARY – Heron Therapeutics has agreed to sell substantially all of its operating assets to CorMedix Therapeutics in a transaction valued at about $222.6 million upfront when announced, a deal that would end the Cary company’s current biotechnology operations while leaving it as a publicly traded company.
Under the asset purchase agreement filed with the U.S. Securities and Exchange Commission, CorMedix would pay $145 million in cash, subject to closing adjustments, and issue 14,583,333 shares of its common stock. Those shares were worth about $77.6 million at CorMedix’s Nov. 6 closing price, producing the announced upfront value. Because the share count is fixed, the stock portion’s market value can change before closing.
Heron also could receive as much as $55 million in earn-out payments tied to 2028 sales of ZYNRELEF. The agreement provides a 5% royalty on the portion of combined annual sales above $25 million for CINVANTI, SUSTOL and products covered by a development and license agreement during 2027 through 2029.
The transaction would transfer Heron’s four commercial-stage products: ZYNRELEF for postoperative pain, APONVIE for postoperative nausea and vomiting, and CINVANTI and SUSTOL for chemotherapy-related nausea and vomiting. CorMedix says the products fit its commercial network in hospitals, ambulatory surgery centers and infusion centers.
The business consequence for North Carolina is larger than a portfolio change. Heron says it would exit its current biotechnology business and historical operations after closing. It would remain publicly traded and retain cash, CorMedix shares, rights to future earn-outs and royalties, and federal and state net operating loss carryforwards. Heron’s board intends to evaluate acquisitions, investments and other strategic transactions after the sale.
The agreement also leaves a material workforce question for the Cary company. CorMedix may make employment offers to Heron business employees through 10 days before closing, and workers who accept would transfer without a break in service. The agreement provides severance treatment for eligible employees who do not receive qualified offers and are terminated. Triangle Business Journal separately reported on the transaction and its potential workforce effect. Neither the agreement nor the companies’ announcement states how many employees will transfer.
CorMedix projects $45 million to $60 million in annualized operating cost savings by the end of 2027, primarily from eliminating overlapping commercial, general and administrative, and public-company expenses. That estimate is a company forecast rather than a completed result.
To help fund the acquisition, CorMedix entered a $150 million senior secured term-loan facility and expects to draw $75 million at closing. Heron plans to repay its working-capital credit facility. Rubric Capital Management also agreed to exchange about $37.8 million in Heron convertible-note principal and accrued interest for part of the CorMedix stock Heron receives.
The boards of both companies approved the agreement. Closing is expected in the first quarter of 2027, but it still requires approval from Heron shareholders, expiration or termination of the applicable federal antitrust waiting period and other customary conditions. Heron shareholders holding about 22% of the company’s outstanding stock had entered voting agreements supporting the transaction when it was announced.
